Yao Wu
Yao Wu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Haojie Sun2 shared publications
- Hua Zhang
School of Nursing, Hainan Medical University
2 shared publications - Lurong Cai2 shared publications
- Mingxin He
Department of Intensive Care Unit, Peking University Shenzhen Hospital, Shenzhen, 518036, Guangdong, China, pkuszh.com
2 shared publications - Minxiang Li2 shared publications
- Pengfei Cheng
Faculty of Medicine, Macau University of Science and Technology, Taipa, 999078, Macau, China, must.edu.mo
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e104186
Effectiveness of Conversational Agents for Depression and Anxiety: Systematic Review and Network Dose-Response Meta-Analysis of Agent Types, Dose, and Human Support
Background: Conversational agents (CAs) are increasingly used to deliver scalable interventions for depression and anxiety, but existing evidence has often treated these tools as a single category. The comparative effectiveness of different agent types, intervention doses, and levels of human support remains unclear. Objective: This review systematically evaluated the comparative effectiveness of various CA modalities and levels of human support, as well as potential dose-response relationships across different CA types. Methods: A comprehensive search of PubMed, Embase, Web of Science, Scopus, Ovid, CINAHL, and Psychology and Behavioral Sciences Collection (PBSC) databases was conducted from inception to December 2025. Eligible studies were randomized controlled trials (RCTs) evaluating CA-based interventions. We conducted a random-effects network meta-analysis (NMA) using postintervention outcomes and assessed inconsistency and risk of bias (RoB). Evidence certainty was assessed using the CINeMA (confidence in network meta-analysis) framework. Where data permitted, model-based network dose-response meta-analysis (MBNMA) was performed to examine dose-response associations. Results: A total of 41 studies (n=7577) were included. NMA showed that AI-enhanced intensive human support (AEIHS) appeared to produce greater symptom improvement for depression and anxiety compared with pure human digital guidance (PHDG; Hedges g=–4.28, 95% CI –5.56 to –2.99) and open-ended multimodal-enhanced chatbot (OEMM; Hedges g=–4.49, 95% CI –6.31 to –2.66), whereas most other comparisons were not statistically significant. MBNMA indicated that goal-oriented conversational agent (GOCA) and highly structured modular chatbot (HSMC) appeared to exhibit nonlinear effects, with preliminary evidence suggesting potentially enhanced response at low-to-moderate doses, though these findings require further investigation. However, publication bias was detected for depression (Egger P=.02), and the overall certainty of evidence was very low, primarily due to RoB, indirectness, and imprecision. Conclusions: While hybrid CA models with enhanced human involvement appeared to show potential advantages over fully automated systems, the evidence base remains limited. The very low certainty of evidence constrains confidence in comparative rankings and dose recommendations. Future high-quality trials are needed to establish optimal CA architectures and intervention doses for scalable mental health care. Trial Registration: PROSPERO CRD420251145207; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251145207
- 13 November 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e104186
Open AccessEffectiveness of Conversational Agents for Depression and Anxiety: Systematic Review and Network Dose-Response Meta-Analysis of Agent Types, Dose, and Human Support
Background: Conversational agents (CAs) are increasingly used to deliver scalable interventions for depression and anxiety, but existing evidence has often treated these tools as a single category. The comparative effectiveness of different agent types, intervention doses, and levels of human support remains unclear. Objective: This review systematically evaluated the comparative effectiveness of various CA modalities and levels of human support, as well as potential dose-response relationships across different CA types. Methods: A comprehensive search of PubMed, Embase, Web of Science, Scopus, Ovid, CINAHL, and Psychology and Behavioral Sciences Collection (PBSC) databases was conducted from inception to December 2025. Eligible studies were randomized controlled trials (RCTs) evaluating CA-based interventions. We conducted a random-effects network meta-analysis (NMA) using postintervention outcomes and assessed inconsistency and risk of bias (RoB). Evidence certainty was assessed using the CINeMA (confidence in network meta-analysis) framework. Where data permitted, model-based network dose-response meta-analysis (MBNMA) was performed to examine dose-response associations. Results: A total of 41 studies (n=7577) were included. NMA showed that AI-enhanced intensive human support (AEIHS) appeared to produce greater symptom improvement for depression and anxiety compared with pure human digital guidance (PHDG; Hedges g=–4.28, 95% CI –5.56 to –2.99) and open-ended multimodal-enhanced chatbot (OEMM; Hedges g=–4.49, 95% CI –6.31 to –2.66), whereas most other comparisons were not statistically significant. MBNMA indicated that goal-oriented conversational agent (GOCA) and highly structured modular chatbot (HSMC) appeared to exhibit nonlinear effects, with preliminary evidence suggesting potentially enhanced response at low-to-moderate doses, though these findings require further investigation. However, publication bias was detected for depression (Egger P=.02), and the overall certainty of evidence was very low, primarily due to RoB, indirectness, and imprecision. Conclusions: While hybrid CA models with enhanced human involvement appeared to show potential advantages over fully automated systems, the evidence base remains limited. The very low certainty of evidence constrains confidence in comparative rankings and dose recommendations. Future high-quality trials are needed to establish optimal CA architectures and intervention doses for scalable mental health care. Trial Registration: PROSPERO CRD420251145207; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251145207
- Open Access
- 9 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Effectiveness of Conversational Agents for Depression and Anxiety: Systematic Review and Network Dose-Response Meta-Analysis of Agent Types, Dose, and Human Support (Preprint)
BACKGROUND Conversational agents (CAs) are increasingly used to deliver scalable interventions for depression and anxiety, but existing evidence has often treated these tools as a single category. The comparative effectiveness of different agent types, intervention doses, and levels of human support remains unclear. OBJECTIVE This review systematically evaluated the comparative effectiveness of various CA modalities and levels of human support, as well as potential dose-response relationships across different CA types. METHODS A comprehensive search of PubMed, Embase, Web of Science, Scopus, Ovid, CINAHL, and Psychology and Behavioral Sciences Collection (PBSC) databases was conducted from inception to December 2025. Eligible studies were randomized controlled trials (RCTs) evaluating CA-based interventions. We conducted a random-effects network meta-analysis (NMA) using postintervention outcomes and assessed inconsistency and risk of bias (RoB). Evidence certainty was assessed using the CINeMA (confidence in network meta-analysis) framework. Where data permitted, model-based network dose-response meta-analysis (MBNMA) was performed to examine dose-response associations. RESULTS A total of 41 studies (n=7577) were included. NMA showed that AI-enhanced intensive human support (AEIHS) appeared to produce greater symptom improvement for depression and anxiety compared with pure human digital guidance (PHDG; Hedges g=–4.28, 95% CI –5.56 to –2.99) and open-ended multimodal-enhanced chatbot (OEMM; Hedges g=–4.49, 95% CI –6.31 to –2.66), whereas most other comparisons were not statistically significant. MBNMA indicated that goal-oriented conversational agent (GOCA) and highly structured modular chatbot (HSMC) appeared to exhibit nonlinear effects, with preliminary evidence suggesting potentially enhanced response at low-to-moderate doses, though these findings require further investigation. However, publication bias was detected for depression (Egger P=.02), and the overall certainty of evidence was very low, primarily due to RoB, indirectness, and imprecision. CONCLUSIONS While hybrid CA models with enhanced human involvement appeared to show potential advantages over fully automated systems, the evidence base remains limited. The very low certainty of evidence constrains confidence in comparative rankings and dose recommendations. Future high-quality trials are needed to establish optimal CA architectures and intervention doses for scalable mental health care. CLINICALTRIAL PROSPERO CRD420251145207; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251145207
- 9 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEffectiveness of Conversational Agents for Depression and Anxiety: Systematic Review and Network Dose-Response Meta-Analysis of Agent Types, Dose, and Human Support (Preprint)
BACKGROUND Conversational agents (CAs) are increasingly used to deliver scalable interventions for depression and anxiety, but existing evidence has often treated these tools as a single category. The comparative effectiveness of different agent types, intervention doses, and levels of human support remains unclear. OBJECTIVE This review systematically evaluated the comparative effectiveness of various CA modalities and levels of human support, as well as potential dose-response relationships across different CA types. METHODS A comprehensive search of PubMed, Embase, Web of Science, Scopus, Ovid, CINAHL, and Psychology and Behavioral Sciences Collection (PBSC) databases was conducted from inception to December 2025. Eligible studies were randomized controlled trials (RCTs) evaluating CA-based interventions. We conducted a random-effects network meta-analysis (NMA) using postintervention outcomes and assessed inconsistency and risk of bias (RoB). Evidence certainty was assessed using the CINeMA (confidence in network meta-analysis) framework. Where data permitted, model-based network dose-response meta-analysis (MBNMA) was performed to examine dose-response associations. RESULTS A total of 41 studies (n=7577) were included. NMA showed that AI-enhanced intensive human support (AEIHS) appeared to produce greater symptom improvement for depression and anxiety compared with pure human digital guidance (PHDG; Hedges g=–4.28, 95% CI –5.56 to –2.99) and open-ended multimodal-enhanced chatbot (OEMM; Hedges g=–4.49, 95% CI –6.31 to –2.66), whereas most other comparisons were not statistically significant. MBNMA indicated that goal-oriented conversational agent (GOCA) and highly structured modular chatbot (HSMC) appeared to exhibit nonlinear effects, with preliminary evidence suggesting potentially enhanced response at low-to-moderate doses, though these findings require further investigation. However, publication bias was detected for depression (Egger P=.02), and the overall certainty of evidence was very low, primarily due to RoB, indirectness, and imprecision. CONCLUSIONS While hybrid CA models with enhanced human involvement appeared to show potential advantages over fully automated systems, the evidence base remains limited. The very low certainty of evidence constrains confidence in comparative rankings and dose recommendations. Future high-quality trials are needed to establish optimal CA architectures and intervention doses for scalable mental health care. CLINICALTRIAL PROSPERO CRD420251145207; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251145207